Lifeboat Foundation

First described by Nedergaard and her colleagues in 2012, the glymphatic system is the brain’s unique waste removal process that uses cerebrospinal fluid (CSF) to wash away excess proteins generated by energy hungry neurons and other cells in the brain during normal activity.

A drug used to induce labor in pregnant women has been shown to reactivate tiny waste-clearing pumps in the brains of old mice. The finding could hold promise as a new way to fight Alzheimer’s and Parkinson’s diseases and overall cognitive decline.

When our brains are working properly, there is an excess of proteins that build up from the energy intensive processes that take place between our neurons. Those proteins need to be removed in order for the brain to continue to operate properly. When they aren’t, they can gunk up the works, leading to the beta amyloid and tau protein tangles that are a hallmark of Alzheimer’s disease or the build up of alpha-synuclein that accompanies Parkinson’s.

Continue reading “Common drug restores youthful function to clean up aging brains” »

Understanding the molecular changes underlying aging is important for developing biomarkers and healthy aging interventions. In this study, the authors used comprehensive multi-omics data to reveal nonlinear molecular profiles across chronological ages, highlighting two substantial variations observed around ages 40 and 60, which are linked to increased disease risks.

US findings suggesting ageing is not a slow and steady process could explain spikes in health issues at certain ages.

Preclinical study investigates neuron-targeted partial cellular reprogramming in the hippocampus to mitigate age-related cognitive impairments.

Completely changing your diet can be hard, so a longevity expert and doctor added foods including olive oil to his diet for the healthy aging benefits.

Innovation At The Frontiers Of Aesthetic And Regenerative Medicine — Prof. Dr. Alan Widgerow — Division Chief, Center for Tissue Engineering, UCIrvine — Chief Scientific Officer, Galderma.

Prof. Dr. Alan Widgerow, MBBCh, FCS, MMed, FACS, is Division Chief, Research, Center for Tissue Engineering (https://sites.uci.edu/ctelab/team/) and Adjunct Professor Plastic Surgery, Dept of Plastic Surgery, University of California, Irvine (https://faculty.uci.edu/profile/?facu…) and Chief Scientific Officer and Head of Skin Science Center of Innovation at Galderma (https://www.galderma.com/).

Continue reading “Prof. Dr. Alan Widgerow — Division Chief, Center for Tissue Engineering, UC Irvine / CSO, Galderma” »

Year 2018 face_with_colon_three

Pediatric Research volume 83, pages 223–231 (2018) Cite this article.

Aging is the major risk factor for the development of chronic diseases such as cardiovascular disease, cancer, diabetes, and dementia. Therefore, drugs that slow the aging process may help extend both lifespan and healthspan (the length of time that people are healthy).

In a study published online on February 29 in Medical Research Archives, Albert Einstein College of Medicine researchers evaluated U.S. Food and Drug Administration-approved drugs for their anti-aging potential. In ranking those drugs, they gave equal weight to preclinical studies (i.e., effect on rodent lifespan and healthspan) and clinical studies (i.e., reduced mortality from diseases the drugs were not intended to treat). The four therapeutics judged most promising for targeting aging were SGLT2 inhibitors, metformin, bisphosphonates, and GLP-1 receptor agonists. Since these drugs have been approved for safety and used extensively, the researchers recommend they be evaluated for their anti-aging potential in large-scale clinical trials.

The study’s corresponding author was Nir Barzilai, M.D., director of Einstein’s Institute for Aging Research, professor of medicine and of genetics and the Ingeborg and Ira Leon Rennert Chair in Aging Research at Einstein, and a member of the National Cancer Institute–designated Montefiore Einstein Comprehensive Cancer Center. The lead author was Michael Leone, a medical student at Einstein.

which is widely believed to be the root cause of many age-related diseases.

The study, published today in the journal npj Aging, raises the exciting possibility of a protective agent that could dampen age-related inflammation and restore normal immune function in older adults.

PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) was initially identified at the University of Birmingham in 2015. While the role of the PEPITEM pathway has already been demonstrated in immune-mediated diseases, this is the first data showing that PEPITEM has the potential to increase healthspan in an aging population.